The RDRC is the administrative body responsible for the utilization of radioactive materials in human research subjects for the purpose of obtaining basic information regarding human physiology, pathophysiology, or biochemistry, but not intended for immediate therapeutic, diagnostic, or similar purpose or to determine the safety and effectiveness of a drug in humans. This committee serves as an in-house extension of the Food and Drug Administration (FDA), thus expediting review of protocols and eliminating the need to submit a Notice of Claimed Investigational Exemption for a New Drug (IND) form to the FDA in certain circumstances. The RDRC meets at least 4 times a year and it's responsibilities include, but are not limited to, the following:

• reviewing, approving or disapproving, and monitoring protocols in which radioactive drugs are administered to research subjects
• prescribing special conditions that may be necessary for the safe administration of radioactive material to human research subjects (e.g., additional animal studies) reviewing reports of any adverse effects associated with the use of the radioactive drug in the research study

	Home Staff Manual Calendar Forms News
	This page last modified on Monday April 04, 2005 Indiana University | Purdue University  Any questions or comments regarding this site should be directed to radsafe@iupui.edu